Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer

AW Wyatt, AA Azad, SV Volik, M Annala, K Beja… - JAMA …, 2016 - jamanetwork.com
Importance The molecular landscape underpinning response to the androgen receptor (AR)
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer
(mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to
guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to
perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free
DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor …